Sellas Life Sciences Presents Phase 3 Data Showing GPS Reduces Death Risk 41% in AML Patients
Bitget2026/11/20 19:12- Sellas Life Sciences' galinpepimut-S met the Phase 3 REGAL trial's primary endpoint, reducing death risk by 41% in AML patients in second remission.
- Median overall survival reached 24.0 months with galinpepimut-S versus 14.7 months with best available treatment.
- The hazard ratio was 0.59, with statistical significance at p=0.035.
- The company plans to meet with the FDA while preparing an expedited biologics license application for galinpepimut-S.
- SLS009 also met all primary endpoints in its completed Phase 2 study in relapsed or refractory AML.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Circle issues 500 million USDC on the Solana network

Cardano vs Solana: Analysts and ADA Holders Clash Over Adoption

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share
Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.

